Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEMLIBRA vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX (FIXa) and factor X (FX) to restore the function of missing activated factor VIII (FVIIIa) in patients with hemophilia A. It mimics the cofactor activity of FVIIIa, thereby promoting thrombin generation and hemostasis.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
FDA: Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Subcutaneous loading dose of 3 mg/kg once weekly for 4 weeks, followed by 1.5 mg/kg once weekly; or 3 mg/kg once weekly for 4 weeks, then 3 mg/kg every 2 weeks; or 3 mg/kg once weekly for 4 weeks, then 6 mg/kg every 4 weeks.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life is approximately 26.7 days (range 20–31 days) in healthy subjects and similar in hemophilia A patients, supporting weekly subcutaneous dosing with a loading period.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Emicizumab is a humanized monoclonal antibody; it is catabolized by general protein degradation pathways, not by cytochrome P450 enzymes.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Emicizumab is catabolized via general protein degradation pathways; no specific elimination route data available. In clinical studies, no significant renal or biliary excretion of intact drug has been observed.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
No protein binding data are available for emicizumab; as a monoclonal antibody, it is not bound to plasma proteins in a specific manner but may be subject to nonspecific binding via Fc receptors.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Mean volume of distribution (Vd) is approximately 10.6 L (about 0.14 L/kg for a 70 kg individual), indicating limited distribution primarily to the vascular space.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Subcutaneous administration: Absolute bioavailability is approximately 50–60% after subcutaneous injection.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
No dose adjustment required for mild to moderate renal impairment; not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²) or dialysis.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
No dose adjustment required for mild hepatic impairment (Child-Pugh A); not studied in moderate or severe (Child-Pugh B or C).
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Weight-based dosing: Same as adult (loading 3 mg/kg weekly x4, then maintenance 1.5 mg/kg weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks) for patients weighing ≥5 kg; no data for <5 kg.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
No specific dose adjustment; limited data in patients ≥65 years; use caution due to higher incidence of thromboembolic events.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Thrombotic microangiopathy (TMA) and thromboembolic events: Cases of TMA and thrombotic events (e.g., venous thrombosis, pulmonary embolism) have been reported when emicizumab was used with activated prothrombin complex concentrates (a PCC) for >24 hours or at doses >100 U/kg. Avoid concomitant use of a PCC and monitor for TMA/thrombosis if a PCC is required.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Thrombotic microangiopathy (TMA) and thromboembolic events (see black box warning).,Increased risk of bleeding if emicizumab is co-administered with bypassing agents (e.g., a PCC, r FVIIa).,Discontinue concurrent prophylactic use of bypassing agents; reduce dose and monitor for bleeding when using on-demand bypassing therapy.,Immunogenicity: Development of anti-emicizumab antibodies may reduce efficacy.,Laboratory monitoring: Emicizumab interferes with activated partial thromboplastin time (a PTT)-based coagulation assays; use chromogenic factor VIII activity assay for monitoring.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Absolute: Hypersensitivity to emicizumab or any excipients.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
No known food interactions. Emicizumab is a monoclonal antibody administered subcutaneously and its absorption and efficacy are not affected by food. Patients may take with or without food.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Emicizumab is a recombinant humanized monoclonal antibody (Ig G4) that binds to activated factor IX and factor X. As an immunoglobulin G, it is actively transported across the placenta during the second and third trimesters. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental outcomes were observed in cynomolgus monkeys administered intravenous emicizumab at doses up to 30 mg/kg (approximately 0.9 times the human exposure at the maximum recommended human dose of 6 mg/kg/week) during organogenesis. However, based on the mechanism of action and potential for inducing thrombotic events, there is a theoretical risk of fetal harm, including thromboembolism. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
There are no data on the presence of emicizumab in human milk, effects on the breastfed infant, or milk production. Emicizumab is a large monoclonal antibody (approximately 146 k Da) and is expected to be present in breast milk at low levels due to its size and the transfer of immunoglobulins into milk. The M/P ratio is unknown. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for emicizumab and any potential adverse effects on the breastfed child from the drug or underlying maternal condition.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No specific dosing adjustments are recommended for emicizumab during pregnancy. Pharmacokinetic changes during pregnancy (e.g., increased plasma volume, altered protein binding) may affect drug concentrations, but no dose adjustment studies have been conducted. The drug should be administered as per standard dosing (loading dose of 3 mg/kg for 4 weeks, then maintenance dose of 1.5 mg/kg once weekly, or 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks) unless clinical monitoring indicates a need for adjustment. Close monitoring of clinical response and coagulation status (e.g., activated partial thromboplastin time) is recommended.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Monitor for thromboembolic events, especially in patients with central venous access devices. Do not mix with other coagulation factor products. Administer subcutaneously once weekly for 4 weeks, then every 2 weeks thereafter. For breakthrough bleeding, use recombinant factor VIIa (r FVIIa) rather than activated prothrombin complex concentrate (a PCC) due to thrombotic risk with a PCC. Do not use for immune tolerance induction. Monitor for thrombotic microangiopathy and venous thromboembolism. Emicizumab is a bispecific monoclonal antibody that bridges factor IXa and factor X, restoring hemostasis in hemophilia A patients with or without factor VIII inhibitors.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take exactly as prescribed; do not skip doses or change schedule without consulting your doctor.,Report any signs of blood clots (leg pain/swelling, chest pain, shortness of breath, headache, vision changes) immediately.,Inform all healthcare providers that you are taking emicizumab, especially before any surgery or dental procedures.,Do not use emicizumab if you have a history of severe allergic reaction to the drug or its components.,Store emicizumab in the refrigerator at 2-8°C (36-46°F); do not freeze. Protect from light. Do not shake the vial.,If a dose is missed, take it as soon as possible, then resume the regular schedule. Consult your doctor if more than one dose is missed.,Avoid using activated prothrombin complex concentrate (a PCC) unless specifically instructed by your doctor, as it may increase risk of blood clots.,Keep a record of injection dates and sites; rotate injection sites (abdomen, thigh, upper arm) to reduce injection site reactions.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEMLIBRA vs ACTIQ, answered by our medical review team.
HEMLIBRA is a Antihemophilic that works by Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX (FIXa) and factor X (FX) to restore the function of missing activated factor VIII (FVIIIa) in patients with hemophilia A. It mimics the cofactor activity of FVIIIa, thereby promoting thrombin generation and hemostasis.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEMLIBRA and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEMLIBRA is: Subcutaneous loading dose of 3 mg/kg once weekly for 4 weeks, followed by 1.5 mg/kg once weekly; or 3 mg/kg once weekly for 4 weeks, then 3 mg/kg every 2 weeks; or 3 mg/kg once weekly for 4 weeks, then 6 mg/kg every 4 weeks.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HEMLIBRA and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HEMLIBRA is classified as Category C. Emicizumab is a recombinant humanized monoclonal antibody (IgG4) that binds to activated factor IX and factor X. As an immunoglobulin G, it is actively transported across the place. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.